Sugi Predict

Sugi Predict / Targets / PIK3R5

PIK3R5

Phosphoinositide 3-kinase regulatory subunit · Q8WYR1 · PIK3R5 on Sugi Atlas →

8,931 patent compounds predicted against PIK3R5, 5,695 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7050 SCHEMBL7050 1.00 20/20
SCHEMBL7052 SCHEMBL7052 1.00 20/20
SCHEMBL7070 SCHEMBL7070 1.00 20/20
SCHEMBL7166 SCHEMBL7166 1.00 20/20
SCHEMBL7186 SCHEMBL7186 1.00 20/20
SCHEMBL7257 SCHEMBL7257 1.00 20/20
SCHEMBL7283 SCHEMBL7283 1.00 20/20
SCHEMBL7291 SCHEMBL7291 1.00 20/20
SCHEMBL7499 SCHEMBL7499 1.00 20/20
SCHEMBL7530 SCHEMBL7530 1.00 20/20
SCHEMBL7558 SCHEMBL7558 1.00 20/20
SCHEMBL7575 SCHEMBL7575 1.00 20/20
SCHEMBL7603 SCHEMBL7603 1.00 20/20
SCHEMBL7607 SCHEMBL7607 1.00 20/20
SCHEMBL7619 SCHEMBL7619 1.00 20/20
SCHEMBL7633 SCHEMBL7633 1.00 20/20
SCHEMBL7659 SCHEMBL7659 1.00 20/20
SCHEMBL7693 SCHEMBL7693 1.00 20/20
SCHEMBL7700 SCHEMBL7700 1.00 20/20
SCHEMBL7728 SCHEMBL7728 1.00 20/20

Clinical trials — most relevant to PIK3R5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adjuvant Low Dose Aspirin in Colorectal Cancer PHASE3ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations PHASE3COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) PHASE2ACTIVE_NOT_RECRUITING
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma PHASE1COMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies nanNOT_YET_RECRUITING
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive? nanUNKNOWN
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PIK3R5 binder may also engage these)

ProteinNameSimilarity
O02696 — 1.000 O02696 →
Q3U6Q4 — 0.998 Q3U6Q4 →
Q5SW28 — 0.998 Q5SW28 →
Q5UE93 — 0.997 Q5UE93 →
Q6INI0 — 0.995 Q6INI0 →
Q5ZIB8 — 0.994 Q5ZIB8 →
Q8VDP4 — 0.992 Q8VDP4 →
Q3UJB9 — 0.990 Q3UJB9 →
Q9Z136 — 0.988 Q9Z136 →
Q5R8S0 — 0.988 Q5R8S0 →
O88480 — 0.988 O88480 →
Q8IWE5 — 0.987 Q8IWE5 →
Q9EP53 — 0.987 Q9EP53 →
Q80TQ5 — 0.987 Q80TQ5 →
Q5T011 — 0.987 Q5T011 →
A1L3T7 — 0.986 A1L3T7 →
Q571B6 — 0.986 Q571B6 →
Q96C34 — 0.986 Q96C34 →
Q3T1I9 — 0.986 Q3T1I9 →
Q9JL70 — 0.986 Q9JL70 →
PIK3C2B Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta 0.986 landscape →
A1A4J7 — 0.986 A1A4J7 →
Q8VDR9 — 0.985 Q8VDR9 →
Q80TC6 — 0.985 Q80TC6 →
B1A193 — 0.985 B1A193 →
CCAR2 Cell cycle and apoptosis regulator protein 2 0.985 landscape →
Q8BL43 — 0.985 Q8BL43 →
Q8TF30 — 0.985 Q8TF30 →
Q3UHQ6 — 0.985 Q3UHQ6 →
A0JN53 — 0.985 A0JN53 →